Publication details
Problemaatika pozdní kardiotoxicity po léčbě antracykliny pro maligní onemocnění v dětském věku
| Title in English | Late cardiotoxicity following anthracycline therapy for malignancies in podiatric age |
|---|---|
| Authors | |
| Year of publication | 2002 |
| Type | Article in Periodical |
| Magazine / Source | Cor Vasa |
| MU Faculty or unit | |
| Citation | |
| Field | Paediatry |
| Keywords | Late cardiotoxicity - Anthracyclines - Heart failure |
| Description | Late cardiotoxicity is a serious complication of anthracycline-based chemotherapy in podiatrie age. It is a relatively frequent complication, often with a subelinical course and, in many cases,with a fatal outcome. Clinically, late cardiotoxicity manifesis litself by he development of chronic heart failure. Its incidence, in the first decade following chemotherapy, has been reported to be 5-10%. Based on echocardiographic findings, subclinical cardiotoxicity occurs in 20-65 % , most often takinf the form of increased sysolic left ventricular wall stress, wall thickening and decresad wall excursions, implaired diastolic funetion, and an asympomatic decrese in systolic funtion markes compared with the healthy population. Use of exercise testing raises the indidence of abnormaliteties to as much as 85%.The most important risk mactors of late clinical cardiotoxicity include the magnitude of the total cumulative dose, size of individual bolus anthracyclin doses, age at whit the patients received treatment, and post-treatment follow-up time. The relationship of risk factors to subclinical cardiotoxicity is fairly loose. Long-term follow-up of patients reated, in podiatric age, for malignancy with antrhracyclines, primarily in the second and define a policy on early pharmacological intervention. |
| Related projects: |